The natural history of breast carcinoma: What have we learned from screening?

Cancer

Volumn 86, Issue 3, 1999, Pages 449-462

  Tabár, László ^a   Duffy, Stephen W ^b   Vitak, Bedrich ^c   Chen, Hsiu Hsi ^d   Prevost, Teresa C ^b  

^a FALUN HOSPITAL   (Sweden)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c LINKÖPING UNIVERSITY   (Sweden)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Breast carcinoma; Breast screening; Mammography; Natural history

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGE DISTRIBUTION; AGED; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MASS SCREENING; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; SURVIVAL RATE; SWEDEN;

EID: 0033178443     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990801)86:3<449::AID-CNCR13>3.0.CO;2-Q     Document Type: Article

References (28)

1. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Amer 1992;30:187-210.
2. Chen HH, Duffy SW, Tabar L, Day NE. Markov chain models for progression of breast cancer, part 2: prediction of outcomes for different screening regimes. J Epidemiol Biostat 1997;2:25-35.
3. Tabar L, Fagerberg G, Day NE, Duffy SW, Kitchin RM. Breast cancer treatment and natural history: new insights from result of screening. Lancet 1992;339:412-4.
4. Duffy SW, Tabar L, Fagerberg G, Gad A, Grontoft O, South MC, et al. Breast screening, prognostic factors and survival-results from the Swedish two-county study. Br J Cancer 1991;64:1133-8.
5. International Union Against Cancer. TNM classification of malignant tumors. Berlin: Springer-Verlag, 1987.
6. Bloom HJG, Richardson WW. Histologic grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.
7. Scarff RW, Torloni H. Histologic typing of breast tumors. International Histological Classification of Tumors. No. 2. Geneva: World Health Organization, 1968.
8. Chen HH, Duffy SW, Tabar L, Day NE. Markov chain models for progression of breast cancer, part 1: tumor attributes and the preclinical screen-detectable phase. J Epidemiol Biostat 1997;2:9-23.
9. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med 1998;339:941-6.
10. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer 1996;66:413-9.
11. Chen HH. Mathematical models for progression of breast cancer and evaluation of breast cancer screening [Ph.D. thesis]. Cambridge, UK: Univ. of Cambridge, 1995.
12. Chen HH, Duffy SW, Tabar L. A Markov chain method to estimate the tumor progression rate from preclinical to clinical phase, sensitivity and positive predictive value for mammography in breast cancer screening. Statistician 1996;45: 1-11.
13. Lesser ML, Rosen PP, Kinne DW. Multicentricity and bilaterality in invasive breast carcinoma. Surgery 1982;91:234-40.
14. Connor AJM, Pinder SE, Elston CW, Bell JA, Wencyk P, Robertson JFR, et al. Intratumoural heterogeneity of proliferation in invasive breast carcinoma evaluated with MIB1 antibody. Breast 1997;6:171-6.
15. Teixera MR, Pandis N, Bardi G, Andersen JA, Mitelman F, Heim S. Clonal heterogeneity in breast cancer: karyotypic comparisons of multiple intra and extra-tumorous samples from 3 patients. Int J Cancer 1995;63:63-8.
16. Chen HH, Duffy SW, Tabar L. A mover-stayer mixture of Markov chain models for the assessment of dedifferentiation and tumour progression in breast cancer. J Appl Stat 1997;24:265-78.
17. Organizing Committee and Collaborators, Falun Meeting. Breast cancer screening with mammography in women aged 40-49 years. Int J Cancer 1996;68:693-9.
18. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of Swedish randomised studies. Lancet 1993;341: 973-8.
19. Kerlikowske K. Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. Monogr Natl Cancer Inst 1997;22:79-86.
20. Hendrick RE, Smith RA, Rutledge JH, Smart CR. Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials. Monogr Natl Cancer Inst 1997;22:87-92.
21. Wald N, Chamberlain J, Hackshaw A. Report of the European Society for Mastology: Breast Cancer Screening Evaluation Committee. Breast 1993;2:209-16.
22. Peer PGM, Holland R, Hendriks JHCL, Mravunac M, Verbeek ALM. Age-specific effectiveness of the Nijmegen population-based breast cancer-screening program: assessment of early indicators of screening effectiveness. J Natl Cancer Inst 1994;86:436-41.
23. Linell F, Ljunberg O, Andersson I. Breast carcinoma aspects of early stages, progression and related problems. APMIS Suppl 1980;272:63-101.
24. Anderson TJ, Lamb J, Alexander F, Lutz W, Chetty U, Forrest AP, et al. Comparative pathology of prevalent and incident cancers detected by breast screening. Lancet 1986;i:519-23.
25. Walter SD, Day NE. Estimation of the duration of a preclinical state using screening data. Am J Epidemiol 1983;118: 865-86.
26. Van Oortmarssen GJ, Habbema JD, van der Mass PJ, de Koning HJ, Collette HJ, Verbeek AL, et al. A model for breast cancer screening. Cancer 1990;66:1601-12.
27. Todd JH, Dowie C, Williams MR, Elston CW, Ellis IO, Hinton CP, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987;56:489-92.
28. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The Nottingham Prognostic Index applied to 9149 patients from the studies of the Danish Breast Cancer Co-operative Group. Breast Cancer Res Treat 1994;32:281-90.